T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer
T2 Biosystems has announced the appointment of Brett Giffin as Chief Commercial Officer, effective November 8, 2021. Giffin will lead global sales, marketing, service, and customer support, succeeding Anthony Pare, who has taken a CEO position at BioPorto A/S. Giffin brings extensive experience from various roles in the medical technology sector, including CEO positions and leadership at notable companies such as Accriva Diagnostics and Boston Scientific. This strategic move aims to enhance T2's growth initiative in the U.S. and international markets.
- Brett Giffin's extensive experience in diagnostics may facilitate effective commercial growth.
- The leadership change is anticipated to strengthen T2 Biosystems' market initiatives.
- Concerns may arise regarding continuity and experience gaps following the leadership transition.
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021.
As Chief Commercial Officer, Mr. Giffin will join the Company’s executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S.
“We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer,” said John Sperzel, Chairman and CEO at T2 Biosystems. “His leadership and deep commercial experience in diagnostics will be invaluable as we pursue our rapid growth plans in the U.S. and international markets.”
Mr. Giffin brings a wealth of industry experience and commercial leadership to T2 Biosystems, having served as Chief Executive Officer for two early stage medical technology companies, as Chief Commercial Officer at Accriva Diagnostics (formerly ITC Medical), and in several sales and marketing leadership roles at Datascope, Covidien, Boston Scientific, and Johnson & Johnson. He began his career as a U.S. Army officer, serving in Panama and Central America.
Mr. Giffin is a Distinguished Military Graduate of the College of William & Mary, and received a bachelor’s degree in Political Science from Christopher Newport University, and a Masters' in Business Management from the University of Phoenix.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our growth plans and the ability of Mr. Giffin to impact those plans, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature.. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission, or SEC, on March 31, 2021, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Media Contact:
Meagan Dominick, Vault Communications
mdominick@vaultcommunications.com
773-369-4255
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
Who is the new Chief Commercial Officer of T2 Biosystems?
What experience does Brett Giffin bring to T2 Biosystems?
Why did T2 Biosystems appoint a new Chief Commercial Officer?
What position did Anthony Pare hold before leaving T2 Biosystems?
